Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

Rhea-AI Summary

Tempus AI, Inc. (NASDAQ: TEM) has launched the beta version of olivia, an AI-enabled personal health concierge app for patients. This innovative app aims to empower individuals to manage their health data holistically. olivia uses generative AI to provide personalized support, offering features such as:

• Seamless connection with healthcare providers
• Comprehensive patient profile creation
• Appointment preparation assistance
• Health monitoring tools

The app addresses the challenge of managing healthcare data across multiple providers and specialties, offering users a centralized platform to organize and access their health information. Tempus CEO Eric Lefkofsky emphasized that olivia leverages the company's investments in AI and multimodal healthcare data aggregation to benefit patients directly.

Positive

• Launch of AI-enabled health management app 'olivia' for patients
• Potential to improve patient care through centralized health data management
• Utilization of generative AI for personalized health insights
• Addressing a significant pain point in healthcare data management for patients

Negative

• availability as the app is currently in beta version
• Potential privacy and security concerns related to aggregating sensitive health data

Tech Expert

Tempus' launch of olivia marks a significant leap in personal health management technology. The app's integration of generative AI for health data aggregation and interpretation is particularly noteworthy. This could potentially disrupt the healthcare tech landscape, offering patients unprecedented control over their medical information.

However, the success of olivia will largely depend on its ability to securely handle sensitive health data and effectively integrate with existing healthcare systems. The app's beta phase will be important in identifying and addressing potential challenges in data privacy, accuracy of AI-generated insights and user experience.

If successful, olivia could set a new standard in patient-centric healthcare technology, potentially influencing future developments in the field and possibly impacting Tempus' market position positively.

Medical Research Analyst

The introduction of olivia represents a significant step towards patient empowerment in healthcare. By aggregating diverse health data and leveraging AI for personalized insights, it addresses a critical gap in current healthcare management systems.

Particularly promising is olivia's potential to improve care coordination for patients with complex or chronic conditions. The app's ability to compile comprehensive health profiles could enhance communication between patients and healthcare providers, potentially leading to more informed decision-making and improved health outcomes.

However, the effectiveness of olivia will depend on the accuracy of its AI algorithms and the comprehensiveness of its data integration capabilities. The beta phase will be important in assessing these aspects and refining the app's functionality.

Financial Analyst

The launch of olivia could potentially open up new revenue streams for Tempus, diversifying its offerings beyond its core business of AI-driven precision medicine. This move into the consumer health tech space could broaden Tempus' market reach and enhance its competitive position.

However, it's important to note that the app is currently in beta phase and its financial impact remains to be seen. The success of olivia will depend on factors such as user adoption rates, monetization strategy and potential partnerships with healthcare providers or insurers.

Investors should monitor key metrics during the beta phase, including user engagement, data integration capabilities and any announced partnerships. While olivia shows promise, its contribution to Tempus' bottom line will take time to materialize, making this a long-term consideration for investors.

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently only available to beta users, leverages generative AI to provide patients and their caregivers personal, concierge-style support in managing their health. The app has a suite of features that aggregate and structure an individual's personal health information in one cohesive place, help a user track symptoms, prepare for doctors’ appointments, and more.

The current healthcare system often puts the onus on patients to manage their own healthcare data, which is overly burdensome for those who suffer from chronic conditions. Many patients work with providers across systems and specialties, which may create a barrier to accessing a holistic health profile. olivia aims to equip every individual with the tools and information they need to receive the best possible treatment amidst increasing complexity of clinical care.

olivia’s suite of features include:

• Seamless Connection with Providers: Aggregate health records by connecting directly with healthcare providers from various institutions to upload, organize, and manage health records in one convenient place (this includes clinical data, scans, slides, molecular tests, and more)
• Comprehensive Patient Profile: Create a singular profile that aggregates and structures health data, and allows for the downloading and sharing with clinicians
• Appointment Preparation: Prepare for appointments by compiling relevant health data, documents, and key questions that can help guide productive conversations with providers
• Health Monitoring: Track symptoms, sleep, and diet, highlight key trends, and create a health journal

On top of these features, olivia uses the emerging capabilities of generative AI to provide individuals access to a comprehensive view of their health record and personalized insights simply by asking a question to olivia, leveraging its built-in generative AI-enabled assistant that provides individuals support and access to insights in a personalized and secure manner.

"Serving patients is at the core of our mission, and olivia brings that to life in a way that directly benefits patients by helping them aggregate their healthcare data in one place, so they can leverage it to receive the best care possible,” said Eric Lefkofsky, Founder and CEO of Tempus. “olivia leverages the enormous investments we have made on behalf of physicians to help patients aggregate multimodal healthcare data at scale and use AI to derive real time insights. As AI becomes more pervasive, individuals are going to need tools like olivia to ensure they are getting the very best care for themselves and their loved ones.”

For more commentary on olivia from Tempus Founder and CEO, Eric Lefkofsky, visit https://www.tempus.com/resources/content/blog/meet-olivia/.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact and indicated use of olivia and the timing of the availability of the tool. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912570295/en/

Erin Carron

media@tempus.com

Source: Tempus AI, Inc.

FAQ

What is olivia and when was it launched by Tempus (TEM)?

olivia is an AI-enabled personal health concierge app launched in beta version by Tempus AI, Inc. (NASDAQ: TEM) to help patients manage their health data holistically.

What are the key features of Tempus' olivia app?

Key features of olivia include seamless connection with healthcare providers, comprehensive patient profile creation, appointment preparation assistance, health monitoring tools, and a generative AI-enabled assistant for personalized insights.

How does olivia by Tempus (TEM) aim to benefit patients?

olivia aims to benefit patients by aggregating their healthcare data in one place, helping them prepare for appointments, track symptoms, and access personalized insights through AI, ultimately enabling them to receive better care.

Who is the target user for Tempus' olivia app?

The target users for olivia are patients and their caregivers, particularly those managing chronic conditions or working with multiple healthcare providers across different systems and specialties.